Niki BioSolutions, Inc. — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Niki BioSolutions engaged Thomas Freeburg as Chief Financial Officer effective September 1, 2026, at an annual base salary of $250,000 (with $25,000 deferred pending $3M capital raise; salary increases to $275,000 upon $5M raise). Freeburg receives 50,000 options at $8.83/share (vesting over milestones including 10K filing, quarterly over 8 quarters, and $5M capital raise) plus 25,000 additional options vesting on change-of-control. Standard severance: remaining salary through initial 2-year term or 6 months (whichever greater) if terminated without cause; equity accelerates upon qualifying termination. Non-compete, IP assignment, and 12-month non-solicitation agreements attached.
Why this rating
CFO hire is ordinary corporate governance for public-ready biotech. Salary and option grants (~$250K + equity) are material (~1.3% of $18.7M assets) but standard for role. No M&A, financing, or operational change disclosed—routine executive appointment.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.